|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
M.D. Anderson Cancer Center |
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00047710 |
Purpose
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.
| Condition | Intervention | Phase |
|
Pancreatic Cancer |
Drug: Bevacizumab |
Phase I |
| MedlinePlus related topics: | Cancer Pancreatic Cancer |
| ChemIDplus related topics: | Capecitabine Bevacizumab Pancrelipase Ultrase |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | A Phase I Trial of Concurrent RHUMAB VEGF (BEVACIZUMAB) and Capecitabine-Based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer |
| Estimated Enrollment: | 48 |
| Study Start Date: | September 2002 |
| Estimated Study Completion Date: | November 2004 |
This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion:
Exclusion:
Contacts and Locations
More Information
| Study ID Numbers: | ID02-146 |
| First Received: | October 14, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00047710 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|